April 2022 in “Anti-cancer agents in medicinal chemistry” In this literature review, researchers compiled evidence on repurposed synthetic radioprotective agents, including metformin and simvastatin, that have demonstrated potential in mitigating the side effects of radiotherapy in cancer treatment.
June 2026 in “Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)” This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.
81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.